Abstract
Despite their high degree of identity and even higher homology, the two Kat3 transcriptional coactivators, CBP and p300, have distinct functions, particularly within the Wnt/β-catenin signaling cascade. ICG-001, by directly binding to CBP but not p300, inhibits CBP/β-catenin transcription and has served as an invaluable chemical genomic tool to dissect the Wnt signaling cascade and the divergent roles of these two coactivators. However, to date no direct antagonist of the p300/β-catenin interaction has been reported. We now report the identification and validation of the first highly specific, direct p300/β-catenin antagonists, YH249/250 and their ability to maintain pluripotency in ESC.
Keywords: p300, CBP, Wnt signaling, peptide mimetics, stem cell, pluripotency.
Graphical Abstract
Current Molecular Pharmacology
Title:Specific Direct Small Molecule p300/β-Catenin Antagonists Maintain Stem Cell Potency
Volume: 9
Author(s): Yusuke Higuchi, Cu Nguyen, Shin-Ya Yasuda, Michael McMillan, Kouichi Hasegawa and Michael Kahn
Affiliation:
Keywords: p300, CBP, Wnt signaling, peptide mimetics, stem cell, pluripotency.
Abstract: Despite their high degree of identity and even higher homology, the two Kat3 transcriptional coactivators, CBP and p300, have distinct functions, particularly within the Wnt/β-catenin signaling cascade. ICG-001, by directly binding to CBP but not p300, inhibits CBP/β-catenin transcription and has served as an invaluable chemical genomic tool to dissect the Wnt signaling cascade and the divergent roles of these two coactivators. However, to date no direct antagonist of the p300/β-catenin interaction has been reported. We now report the identification and validation of the first highly specific, direct p300/β-catenin antagonists, YH249/250 and their ability to maintain pluripotency in ESC.
Export Options
About this article
Cite this article as:
Higuchi Yusuke, Nguyen Cu, Yasuda Shin-Ya, McMillan Michael, Hasegawa Kouichi and Kahn Michael, Specific Direct Small Molecule p300/β-Catenin Antagonists Maintain Stem Cell Potency, Current Molecular Pharmacology 2016; 9 (3) . https://dx.doi.org/10.2174/1874467208666150526155146
DOI https://dx.doi.org/10.2174/1874467208666150526155146 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Hexahydropyridoindole Derivative as Prospective Agent Against Oxidative Damage in Pancreatic βCells
Medicinal Chemistry CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders
Mini-Reviews in Medicinal Chemistry In Silico Target Identification and Molecular Docking Studies of Natural Cytotoxic Compound Borivilianoside H
Current Biotechnology The Protein-Protein Interaction-Mediated Inactivation of PTEN
Current Molecular Medicine Editorial:[Special Issue: Post-Translational Proteomics and its Application (Guest Editor: Qing-Yu He)]
Current Proteomics Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets Emerging Evidence for the Role of Neurotransmitters in the Modulation of T Cell Responses to Cognate Ligands
Central Nervous System Agents in Medicinal Chemistry New Generation of Oncolytic Herpes Virus
Current Cancer Therapy Reviews Discovery Approaches for Novel Dyslipidemia Drugs
Current Drug Discovery Technologies Defining and Managing Expectations for Early Immunotherapy Cancer Trials
Reviews on Recent Clinical Trials Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine
Current Drug Metabolism Positron Emitting Tracers in Pre-Clinical Drug Development
Current Radiopharmaceuticals Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic Effects
Current Pharmaceutical Design Hypersensitivity Reactions to Last Generation Chimeric, Umanized and Human Recombinant Monoclonal Antibodies for Therapeutic Use
Current Pharmaceutical Design Aldose Reductase: A Multi-disease Target
Current Enzyme Inhibition MicroRNAs and Cancer: Towards a Personalized Medicine
Current Molecular Medicine General Theory for Multiple Input-Output Perturbations in Complex Molecular Systems. 1. Linear QSPR Electronegativity Models in Physical, Organic, and Medicinal Chemistry
Current Topics in Medicinal Chemistry Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs
Current Protein & Peptide Science Leucine-zipper and Sterile-α Motif Kinase (ZAK): A Potential Target for Drug Discovery
Current Medicinal Chemistry Seeking the 5th Base of DNA Using Chromatographic Methods of Analysis
Current Organic Chemistry